Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis.

Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis.

Clinicopathological studies suggest that Alzheimer's disease (AD) pathology begins ∼10-15 years before the resulting cognitive impairment draws medical attention. Biomarkers that can detect AD pathology in its early stages and predict dementia onset would, therefore, be invaluable for patient c...

Full description

Bibliographic Details
Main Authors: Rebecca Craig-Schapiro, Max Kuhn, Chengjie Xiong, Eve H Pickering, Jingxia Liu, Thomas P Misko, Richard J Perrin, Kelly R Bales, Holly Soares, Anne M Fagan, David M Holtzman
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-04-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3079734?pdf=render

Internet

http://europepmc.org/articles/PMC3079734?pdf=render

Similar Items